Tukavo (Tucatinib 150mg) is a targeted therapy used to treat HER2-positive advanced and metastatic breast cancer, usually in combination with other medicines.
| Composition | Tucatinib |
| Manufacturer | Zydus |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Tuccatinn (Tucatinib 150mg) is a targeted therapy indicated for the treatment of HER2-positive advanced and metastatic breast cancer, often prescribed along with other medications.
| Composition | Tucatinib |
| Manufacturer | BDR |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Tucanat contains Tucatinib, a targeted therapy used to treat HER2-positive breast cancer, often in combination with other medicines. It helps slow cancer growth, prevent spread, and improve survival in advanced or metastatic cases.
| Composition | Tucatinib |
| Manufacturer | Natco |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
